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Objective: Approximately one-quarter of military personnel who deployed to combat sta-
tions sustained one or more blast-related, closed-head injuries. Blast injuries result from
the detonation of an explosive device.The mechanisms associated with blast exposure that
give rise to traumatic brain injury (TBI), and place military personnel at high risk for chronic
symptoms of post-concussive disorder (PCD), post-traumatic stress disorder (PTSD), and
depression are not elucidated.
Methods:To investigate the mechanisms of persistent blast-related symptoms, we exam-
ined expression profiles of transcripts across the genome to determine the role of gene
activity in chronic symptoms following blast-TBI. Active duty military personnel with (1) a
medical record of a blast-TBI that occurred during deployment (n=19) were compared to
control participants withoutTBI (n=17). Controls were matched to cases on demographic
factors including age, gender, and race, and also in diagnoses of sleep disturbance, and
symptoms of PTSD and depression. Due to the high number of PCD symptoms in the
TBI+ group, we did not match on this variable. Using expression profiles of transcripts
in microarray platform in peripheral samples of whole blood, significantly differentially
expressed gene lists were generated. Statistical threshold is based on criteria of 1.5 mag-
nitude fold-change (up or down) and p-values with multiple test correction (false discovery
rate <0.05).
Results:There were 34 transcripts in 29 genes that were differentially regulated in blast-TBI
participants compared to controls. Up-regulated genes included epithelial cell transform-
ing sequence and zinc finger proteins, which are necessary for astrocyte differentiation
following injury.Tensin-1, which has been implicated in neuronal recovery in pre-clinicalTBI
models, was down-regulated in blast-TBI participants. Protein ubiquitination genes, such as
epidermal growth factor receptor, were also down-regulated and identified as the central
regulators in the gene network determined by interaction pathway analysis.
Conclusion: In this study, we identified a gene-expression pathway of delayed neuronal
recovery in military personnel a blast-TBI and chronic symptoms. Future work is needed to
determine if therapeutic agents that regulate these pathways may provide novel treatments
for chronic blast-TBI-related symptoms.
Keywords: traumatic brain injury, military, post-concussive disorder, gene-expression
Abbreviations: ANOVA, analysis of variance; BMI, body-mass index; DSM-IV,
diagnostic and statistical manual of mental disorders, 4th ed; EGFR, epidermal
growth factor receptor; FDR, false discovery rate; IPA, interactive pathway analy-
sis; MARCH8, membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein
ligase; NSI, neurobehavioral symptom inventory; OSA, obstructive sleep apnea;
PCD, post-concussive disorder; PCL-M, PTSD checklist military version; PTEN,
phosphatase and tensin homolog; PTSD,post-traumatic stress disorder; QIDS,quick
inventory of depressive symptomatology; SCID, structured clinical interview for
DSM-III-R; SF-36, short form (36) health survey; TBI, traumatic brain injury; TNS1,
tensin-1; VEGF, vascular endothelial growth factor; WARCAT, warrior administered
retrospective casualty assessment tool; ZC3H12C, zinc finger CCCH-type
containing 12C.
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INTRODUCTION
Improvised explosive devices (IEDs) have induced blast traumatic
brain injuries (TBI) in approximately one-quarter of military
personnel deployed to combat stations in Operations Enduring
Freedom and Iraqi Freedom (1). In addition to the blast wave, blast
events often involve a blunt-force component, placing individuals
at risk for alterations in consciousness, disruptions in memory,
and headaches from both mechanisms of the blast-TBI (2, 3).
Following deployment these military personnel are at high risk
for on-going neurological and psychological symptoms, including
post-concussive disorder (PCD), post-traumatic stress disorder
(PTSD), and depression (4, 5). Our understanding of a com-
plete and precise mechanism of blast-related pathology is limited,
resulting in an inability to determine military personnel at risk for
these chronic disorders, and to inform interventions to mitigate
these risks.
Clinical studies report differential gene expression following
TBI; however, these studies do not include blast-TBI, and most
use post-mortem, neuronal tissue samples obtained from severe
TBI patients (6–10). Studies that use imaging techniques report
cortical thinning in the left superior temporal and frontal gyri
(11) and altered neurocircuitry (12) in military personnel with a
history of blast-TBI and chronic symptoms. These current stud-
ies are limited because they could neither examine the biological
processes that contributed to neuronal compromise nor did they
determine the impact of other variables that may affect gene
expression or morphology of the brain, including comorbid PTSD,
depression, and chronic pain. These considerations are essential,
as not-determining the impact of these complexities can result in
an inability to determine what the consequences are from the blast
itself (13). Although there are advantages of pre-clinical mod-
els of blast, there are also challenges in translating findings that
include differential injury mechanisms in the laboratory, limiting
application to clinical patients including military personnel (14).
Although pre-clinical models are not in agreement in the pref-
erential models of blast-TBI, there is definitive evidence linking
blast-TBIs to neuronal function changes (15). Blast-TBIs result
in cerebral edema and vasospasm, which contribute to global
acute neuronal compromise through an influx of immune cells
and inflammatory processes (16, 17). Within 24 h of blast-TBI, an
up-regulation of glial fibrillary acidic protein, vimentin, and com-
plement component 1 is observed (18), as well as an activation of
microglia (19), which are key to TBI recovery as they propagate
inflammation to neighboring neurons, providing vital protec-
tion. In traditional TBI, microglia communicates with peripheral
immune cells to modulate immune activities (20). Specifically,
microglia interacts with peripheral immune cells, resulting in a
gene-expression signature in the peripheral blood cells that may
be informative of central recovery activities (21). This assertion has
been recently supported in a pre-clinical study that reports similar
micro-RNA changes in the cerebral spinal fluid and serum fol-
lowing a blast, suggesting that peripheral samples provide insights
into neuronal changes following blast (22).
Therefore, we suggest that central neuronal recovery mecha-
nisms may be detected in the periphery through whole blood sam-
ples obtained from military personnel with a history of blast-TBI
who are seeking care for chronic symptoms. To further investigate
this postulation, we enrolled military personnel with medically
documented blast-TBI, as well as controls without TBI. Instru-
ments and a clinical evaluation were undertaken to determine cur-
rent symptoms of PCD, PTSD, depression, and sleep disturbance.
Differentially expressed genes related to blast-TBI were obtained
by comparing military personnel with blast-TBI to matched con-
trols without TBI using a whole-genome approach that elimi-
nates any biased selection of biological targets. We addressed the
possible impact of PTSD, depression, and sleep disturbance on
gene-expression through group matching, on diagnoses of sleep
disturbance, and symptom severity of PTSD and depression. This
approach may provide a minimally invasive opportunity to inves-
tigate the gene-expression pathways that contribute to blast-TBI
pathology in military personnel. We expect this line of research
to ultimately inform pharmacological agents to better treat mil-
itary personnel with chronic symptoms and deficits following a
blast-TBI.
MATERIALS AND METHODS
CLINICAL METHODS
This study was an observational assessment of U.S. military
personnel at the Madigan Army Medical Center who had
been deployed within the previous 18 months. Exclusion criteria
included (1) no history of drug or alcohol abuse in the previous
year and (2) no current medical condition that required substan-
tial treatments (cancer, diabetes, HIV, autoimmune disorders), or
a severe psychiatric condition (i.e., schizophrenia or bipolar disor-
der). Subjects with neurological disorders other than headaches,
e.g., multiple sclerosis, seizure disorders, and a history of stroke,
were excluded. Subjects with blast-TBI were identified by having
a blast-TBI documented in their medical record. Blast-TBI cases
did not require a pre-specified severity of PCD symptoms. Con-
trols neither have a medical history of any TBI in their records
nor report a TBI when asked. Controls were matched to blast-
cases as much as possible on critical variables that would have
influenced gene-expression including the following: age, gender,
race/ethnicity, and diagnoses of sleep disorder, and symptom
severity of PTSD and depression. The medical record was used
to determine the number and type of prescribed medications that
military personnel were prescribed. This study was approved by
the institutional review board at the Madigan Army Medical Cen-
ter, and informed consent was obtained from each individual prior
to any baseline measurements.
Determination of TBI
The case history of TBI was extracted from medical records of
the 117 military personnel enrolled in a larger observational
study. Clinical information obtained includes the following: type
of injury, diagnosis of TBI that includes severity, loss of con-
sciousness, and time since the TBI. To be a blast-TBI case, the
participant must also have reported sustaining a TBI through
administration of the warrior administered retrospective casualty
assessment tool (WARCAT) (23). A negative response to the WAR-
CAT was necessary to be in the control group. This tool obtains
data on possible war-related TBI injuries and post-deployment
injuries, and whether they were injured from mechanisms com-
monly associated with TBI while deployed, whether any injuries
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resulted in an altered mental status indicative of TBI, and/or
whether specific somatic and neuropsychiatric symptoms com-
monly associated with mild TBI occurred after the injury (imme-
diately post-injury and/or post-deployment). The somatic and
neuropsychiatric symptoms were not used to make the diagnosis
of TBI. The diagnosis of mild TBI was made in accordance with
American Congress of Rehabilitation Medicine mild TBI criteria,
which requires an injury event followed by a loss of consciousness
or alteration of mental state and was consistent with criteria for
TBI delineated by the Department of Defense and Department of
Veterans Affairs.
Determination of PCD, PTSD, and depression symptoms
The neurobehavioral symptom inventory (NSI) was used to mea-
sure PCD symptom severity. The NSI is a 22-item measure
designed to evaluate self-reported post-concussion symptoms
(e.g., headache, balance, nausea, etc.). The NSI requires the test
taker to rate the presence/severity of each symptom on a 5-point
scale (none, mild, moderate, severe, very severe). A total score is
obtained by summing the ratings for the 22 items (range= 0–88).
The NSI has a high-internal consistency (total alpha= 0.95; sub-
scale alpha= 0.88–0.92) and reliability (r = 0.88–0.93) (24). This
instrument was administered to all participants.
Symptoms of PTSD were assessed by the PTSD checklist mil-
itary version (PCL-M), resulting in a score between 0 and 80,
with higher numbers indicating the greatest severity (25). The
quick inventory of depressive symptomatology (QIDS) was used
to measure total symptoms of depression, resulting in a score of
0–27 (26). Chronic pain was evaluated by the bodily pain score
from the short form (36) health survey (SF-36). We used this in
conjunction with the medical record to determine a diagnosis of
pain, by either a score lower than 70 for military personnel with a
pain diagnosis in their electronic medical record or a low-bodily
pain subscale score (<30) on the SF-36 (27).
LABORATORY METHODS
RNA sample preparation
Blood samples were collected in PAXgene blood RNA tubes and
processed with PAXgene™ Blood RNA Kits (PreAnalytiX, Qiagen)
for RNA extraction according to the manufacturer’s instruction.
Quality and quantity of extracted RNA were evaluated with the
NanoDrop DN-1000 spectrophotometer (Thermo Fisher Scien-
tific, Wilmington, DE, USA) and the Agilent Bioanalyzer 2100
eukaryotic total RNA Nano assay (Agilent Technologies, Inc., Santa
Clara, CA, USA). The 260/280 ratio ranged 2.03–2.34 and the RNA
integrity numbers (RIN) were >7.0 in all samples.
Microarray gene-expression profiling
Purified RNAs (100 ng) were amplified, fluorescently labeled, and
hybridized to Affymetrix GeneChip Human Gene U133 Plus 2.0
Arrays (Affymetrix, Inc., Santa Clara, CA, USA), which con-
tain more than 54,000 probes representing thousands of specific
gene coding regions. After thorough washing, the raw data were
obtained by laser scanning imaging. All RNA preparation and tran-
scriptome assays were undertaken in the NINR laboratory based
on manufacturer’s protocols.
Data analysis
Descriptive statistics for all demographic and clinical variables
were calculated using SPSS Statistics (IBM SPSS Inc., Chicago,
IL, USA) (Tables 1 and 2). Comparisons were made between
the groups using t -tests. A priori p-values <0.05 were considered
significant.
Microarray data were analyzed for a total of 36 participants
for gene-expression profiles using Partek Genomics Suite software
(Partek Inc., St. Louis, MO, USA). The probe-level robust multi-
chip average background correction, quantile normalization, log2
transformation, and probe-set summarization were performed on
gene-expression intensity values. Multi-way analysis of variance
(ANOVA) mixed models were constructed for differential expres-
sions for both the blast-TBI+PCD (N = 19) and control (N = 17)
groups. Since samples were processed on different dates, batch cor-
rection was applied. Pair-wise comparisons were made by setting
the contrast between blast-TBI and control groups. Significant
differentially expressed gene lists were generated based on cri-
teria of 1.5 magnitude fold-change (up or down), and p-values
corrected for false discovery rate (FDR< 0.05) using the step-up
Benjamini–Hochberg method.
Interactive pathway analysis (IPA) (Qiagen Ingenuity Sys-
tems, Redwood City, CA, USA) was performed on differentially
expressed genes to identify gene interactions and networks asso-
ciated with biological functions.
Clinical variables were compared using ANOVA models
for continuous variables, and chi-square for categorical data.
Although our data were small in sample size, it met the assump-
tions of the tests we used, including ANOVA. Bonferroni correc-
tions were used to adjust for multiple comparisons.
RESULTS
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS
The demographic and clinical characteristics of the 36 partici-
pants used in this analysis are described in Table 1. The blast-TBI
group (N = 19) was group matched to a control group (N = 17)
to ensure that the groups did not differ on any demographic [age,
body-mass index (BMI), gender, race, and military rank] or clinical
characteristics (depression, and PTSD symptom severity and sleep
diagnoses). There was no difference in the total number of military
personnel taking any prescribed medication, or the type of med-
ications, the most common being serotonin reuptake inhibitors
(SSRIs), anti-hypertensive, and prazosin. The mean ages of the
blast-TBI and control groups were 32.0 and 30.9 years, respectively.
The sample was male,primarily Caucasian,and demonstrated high
rates of comorbid symptoms of sleep disorders, depression, and
PTSD. The blast-TBI group reported a far greater severity of PCD
symptoms compared to controls.
All 19 participants in the TBI group experienced a blast injury,
and 84.25% had a loss of consciousness following the blast-TBI.
By medical diagnosis in theater, approximately 78.95% had a mild
blast-TBI, and 21.05% of the sample was diagnosed with a mod-
erate blast-TBI. In this sample, a brain contusion was reported to
have occurred at the time of the blast in 36.84% of the sample,
and all were determined to be mild in severity. More than half of
the sample had more than one blast-TBI (52.6%), and approxi-
mately one-third had (38.8%) three or more blast-TBIs. The time
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Table 1 | Demographics and clinical characteristics for blast-TBI+PCD (N =19) and control (N =17) groups.
TBI+PCD (N =19) Control (N =17) Significance
Mean age in years (SD) 32.00 (9.04) 30.94 (7.48) F 1,35=0.14, p=0.72
Mean BMI (SD) 29.30 (3.76) 31.65 (4.82) F 1,35=2.03, p=0.16
Gender, % (No) N/A
Male 100.0% (19) 100.0% (17)
Race, % (No) χ2=4.22, p=0.52
Caucasian 73.8% (14) 58.8% (10)
Mixed 15.8% (3) 11.8% (2)
All other 10.4% (2) 19.4% (5)
Rank, % (No) χ2=0.97, p=0.62
Lower enlisted 57.9% (11) 58.8% (10)
Senior NCO 36.8% (7) 35.3% (6)
Officer 5.2% (1) 5.9% (1)
Sleep diagnoses, % (No) χ2=2.79, p=0.43
OSA 10.5% (2) 5.9% (1)
Insomnia 31.6% (8) 23.5% (4)
OSA+ insomnia 31.5% (6) 58.8% (10)
None 15.8% (3) 11.8% (2)
Depression severity (QIDS) 9.6 (5.1) 8.7 (4.8) F 1,35=2.42, p=0.10
PTSD severity (PCL-M) 32.05 (18.8) 29.90 (15.1) F 1,35=2.31, p=0.14
Prescribed medications, % yes (no) 36.8% (6) 41.2% (7) χ2=1.51, p=0.51
SSRI 15.8% (3) 11.8% (2)
Prazosin 21.1% (4) 17.6% (3)
Anti-hypertensive 15.8% (3) 23.5% (4)
TBI, traumatic brain injury; PCD, post-concussive disorder; SD, standard deviation; no, number; NCO, non-commissioned officer; BMI, body-mass index; OSA, obstruc-
tive sleep apnea; QIDS, quick inventory of depressive symptomatology; PTSD, post-traumatic stress disorder; PCL-M, PTSD checklist military version; SSRI, selective
serotonin reuptake inhibitor.
since TBI varied, with 3–6 months, 6–12 months, and more than
12 months having elapsed for 15.8, 31.6, and 52.7% of the group,
respectively.
The breakdown of the 22 components of the NSI for both the
blast group and control group are shown in Table 2. Scores on 17
of the 22 components were significantly different between the two
groups, based on a p-value of 0.05, and adjustment for multiple
comparisons.
DIFFERENTIAL GENE EXPRESSION IN TBI
Differential expression of transcripts between blast-TBI and con-
trol groups resulted in multiple down-regulated (Table 3) and
up-regulated genes (Table 4). Notable down-regulated genes are
membrane-associated ring finger (C3HC4) 8, E3 ubiquitin pro-
tein ligase (MARCH8, −1.6123 fold-change), tensin-1 (TNS1,
−2.368 fold-change), tripartite motif containing 58 (TRIM58,
−1.918), Kruppel-like factor 1 (KLF1,−1.766), WNK lysine defi-
cient protein kinase 1 (WNK1,−1.630), ankyrin1 (ANK1,−1.628),
and epidermal growth factor receptor (EGFR,−1.526). Differen-
tially expressed gene pathways are shown in the network figure
(Figure 1), generated from the ingenuity knowledge database.
Figure 1 indicates that the majority of the genes relate to ubiquitin
C (UBC), and that EGFR is related to multiple gene-networks.
Sub-group analyses
We separated subjects with moderate TBI from mild, and also did a
subsequent analysis on TBIs within the last 12 months compared to
subjects with a TBI more than 12 months ago. Lastly, we grouped
subjects by multiple blast-TBIs, compared to subjects with only
one blast-TBI. None of these analyses yielded a significant find-
ing over the 1.5-fold-threshold, with the adjustment for multiple
comparisons.
DISCUSSION
To our knowledge this is the first study to report differential gene
expression in the peripheral blood of military personnel with a
history of blast-TBI during deployment compared to matched
controls. Here, we report that differential expression of genes
involved in the secondary injury processes may contribute to the
long-term symptoms of PCD that are common among this group.
These findings are significant because the genes we report to be
differentially expressed are related to neuronal recovery following
TBI, suggesting for the first time that a peripheral sample of blood
may be used to better understand central processes in a sample of
military personnel who have chronic blast-TBI related symptoms.
Specifically, our finding of a reduction in the membrane-
associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase
(MARCH8) as well as tripartite motif containing 58 (TRIM58)
in military personnel with blast-TBI suggest that adequate func-
tionality of the ubiquitin proteasome is essential for recovery from
blast-TBI. Protein ubiquitination protects neurons from the detri-
mental impact of accumulating reactive oxygen, nitrogen species,
and free release of zinc initiates (28) by initiating the removal of
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Table 2 | Neurobehavioral symptom inventory for blast-TBI+PCD
(N =19 and control (N =17) groups.
TBI+PCD
(N =19)
Control
(N =17)
Significance
Forgetfulness 3.19 (0.75) 1.71 (1.16) F1,35=18.72, p<0.001
Concentration 2.69 (0.70) 1.29 (1.16) F1,35=17.13, p<0.001
Slowed thinking 2.37 (0.89) 1.06 (1.30) F1,35=11.44, p=0.002
Dizziness 1.19 (0.83) 0.41 (0.51) F1,35=10.56, p=0.003
Headache 2.31 (1.08) 1.12 (1.05) F1,35=10.36, p=0.003
Hearing problems 2.06 (1.18) 0.88 (1.22) F1,35=7.96, p=0.008
Sleep difficulty 3.37 (0.72) 2.59 (0.87) F1,35=7.96, p=0.008
Nausea 0.94 (1.06) 0.18 (0.39) F1,35=7.63, p=0.010
Decision making 2.25 (1.07) 1.24 (1.15) F1,35=6.91, p=0.013
Irritability 2.81 (0.66) 1.88 (1.32) F1,35=6.46, p=0.016
Balance 1.19 (0.91) 0.53 (0.62) F1,35=5.93, p=0.021
Numbness 2.06 (1.57) 0.82 (1.38) F1,35=5.82, p=0.022
Coordination 1.38 (0.81) 0.65 (0.93) F1,35=5.73, p=0.023
Frustration 2.44 (0.96) 1.53 (1.23) F1,35=5.52, p=0.025
Light sensitivity 1.31 (1.08) 0.59 (0.87) F1,35=4.54, p=0.041
Taste/smell changes 0.81 (0.98) 0.18 (0.73) F1,35=4.51, p=0.042
Noise sensitivity 1.50 (1.21) 0.65 (1.12) F1,35=4.44, p=0.043
Vision problems 1.31 (1.14) 0.59 (0.94) F 1,35=3.99, p=0.054
Anxiety 2.75 (1.24) 1.82 (1.51) F 1,35=3.69, p=0.064
Depression 2.00 (1.03) 1.35 (1.27) F 1,35=2.55, p=0.120
Appetite changes 1.56 (1.32) 0.88 (1.22) F 1,35=2.38, p=0.133
Fatigue 2.75 (1.00) 2.47 (2.50) F 1,35=0.17, p=0.680
TBI, traumatic brain injury; PCD, post-concussive disorder.
Italic font: significant group difference. NSI scale ranges from 0 to 4 for each item,
with a 0 indicating that the symptom is not present.
oxidized or misfolded proteins that result following injury (18).
In fact, higher concentrations of the protein encoded by UBC-
terminal hydrolase-L1 is one of the primary proteomic biomarkers
of acute TBI (29–31), with high concentrations being related to the
onset of chronic symptoms in pediatric patients (30).
Pre-clinical models link blast-TBIs to the activation of the
autonomous nervous system and the neuroendocrine–immune
system, suggesting that neuronal pathology results from the
over-activation of multiple biological systems (32). For exam-
ple, blast-TBIs result in increases in inflammatory cytokines and
chemokines, as well as orexin A, and neuropilin-2 release (33).
Pre-clinical models also link blast to an increase in UCH-L1 in
blood and CSF, with CSF elevations lasting for 14 days, as well as
increases in other putative biomarkers of brain injury glial fib-
rillary acid protein, and neuron-specific enolase (34). Minimiza-
tion of the ubiquitin pathway following a blast-TBI, by inducing
hypothermic conditions, resulted in less UCH-L1 activity follow-
ing blunt force and a reduction of neuronal and glial damage (35).
Therefore, additional studies are needed to determine how the
ubiquitin pathway relates to neuronal damage following blast, and
if it may be a pharmacological target to promote neuronal recovery
from blast.
Therefore, reduction in the expression of this gene suggests
that this process is down-regulated and may contribute to chronic
neurological symptoms and impairments in military personnel
with a blast-TBI. This assertion is further supported by pre-clinical
models that link down-regulation in protein ubiquitination genes
to poor neuronal repair (36), greater neuronal loss (37, 38), and
less neurodegeneration (39). A previous study has linked increased
zinc accumulations to reduced function of the ubiquitin pathway
in cultured neurons (40). Additional studies that include acute
biomarkers and determine changes in gene-expression over time
are needed to determine the role of protein ubiquitination in blast-
TBI recovery, as this line of research may inform pharmacological
agents to promote recovery.
We also report reduced expression of TNS1, a gene that is
pivotal to neuronal recovery following a TBI, which works in coor-
dination with protein ubiquitination genes. Thus, our finding of a
reduction in TNS1 in conjunction with reductions in protein ubiq-
uitination genes leads us to question if a down-regulation in these
genes may compromise neuronal recovery following blast-TBI,
resulting in chronic neurological symptoms and deficits. Increases
in the activity of TNS1 are linked to a risk for the onset of can-
cer and allergy induced asthma (41, 42). In a recent study, TBIs
have been associated with an increased risk for brain cancer (43),
suggesting that this TNS1 activity may increase morbidity risks
following TBI. Therefore, additional studies are needed to validate
our finding and to determine how TNS1 may relate to blast-TBI
and chronic neurological symptoms.
Axonal injury and degeneration, whether primary or secondary,
contribute to the morbidity and mortality risks following TBI,
which is shaped in part by the EGFR pathway through the activa-
tion of astrocytes. Astrocytes promote neuronal survival through
potentiation of collateral synapses, migration of neuronal prog-
enitor cells, and differentiation of glial progenitor cells following
TBI (44, 45). EGFR is also a peripheral precursor for vascular
endothelial growth factor (VEGF), which plays a role in angio-
genesis and has been shown to be neuroprotective following TBI
in pre-clinical models (46–48). Thus, EGFR is similar to protein
ubiquitination, down-regulation, and may occur following blast-
TBI, and place military personnel at greater risk for poor neuronal
repair and insufficient regeneration, resulting in the development
of chronic symptoms and deficits. Future studies that utilize bio-
markers collected sooner following the blast-TBI in larger and
more representative samples may determine this relationship.
Although many of the genes that were significantly different
in the blast-TBI group compared to controls related to neuronal
compromise, a number of genes were not. One such gene was
up-regulation of MLF1 interacting protein, a gene that suppresses
cancer cell progression (49), as well the gene for outer dense fiber
of sperm tails 2-like (ODF2L), which relates to defective spermato-
zoa (50). In addition, we also did not observe alterations in genes
linked to blast-TBI in pre-clinical models, including inflamma-
tion (33), and putative biomarkers of brain injury, including glial
fibrillary acid protein and neuron-specific enolase (34). It may
be that since many participants in our sample population had a
TBI that occurred over a year prior to enrollment, other non-
related processes may have occurred, possibly contributing to the
identification of non-expected candidates.
Our findings are limited by the cross-sectional nature of
the study in a relatively small sample of military personnel.
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Table 3 | Significantly down-regulated genes comparing blast-TBI+PCD (N =19) to control (N =17) groups.
Probe-set ID Gene symbol Gene title p-Value Fold-change
221748 TNS1 Tensin-1 0.00062 −2.3682
215047 TRIM58 Tripartite motif containing 58 0.00012 −1.9188
210504 KLF1 Kruppel-like factor 1 (erythroid) 0.00094 −1.7663
221246 TNS1 Tensin-1 0.00061 −1.6963
228770 GPR146///LOC100505551///
LOC100505568
G protein-coupled receptor 146///uncharacterized
LOC100505551///uncharacterized LOC
0.00029 −1.684
221824 8-Mar Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin
protein ligase
0.0001 −1.6534
201912 GSPT1 G1 to S phase transition 1 0.00057 −1.6369
212430 RBM38 RNA binding motif protein 38 0.00092 −1.6368
1555068 WNK1 WNK lysine deficient protein kinase 1 0.00017 −1.6307
218863 TNS1 Tensin-1 0.00066 −1.6286
205389 ANK1 Ankyrin 1, erythrocytic 0.00088 −1.6284
224690 FAM210B Family with sequence similarity 210, member B 0.00054 −1.6254
224789 DCAF12 DDB1 and CUL4 associated factor 12 0.00019 −1.618
202242 TSPAN7 Tetraspanin 7 0.00015 −1.6131
231933 March8 Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin
protein ligase
0.00065 −1.6123
224693 FAM210B Family with sequence similarity 210, member B 0.0008 −1.6016
227935 PCGF5 Polycomb group ring finger 5 0.00077 −1.5973
207801 RNF10 Ring finger protein 10 0.00057 −1.5533
217736 EIF2AK1 Eukaryotic translation initiation factor 2-alpha kinase 1 0.00035 −1.5522
202974 MPP1 Membrane protein, palmitoylated 1, 55 kDa 0.00079 −1.5427
221958 WLS Wntless homolog (Drosophila) 0.00085 −1.5417
225167 FRMD4A FERM domain containing 4A 0.00037 −1.5352
1565484 EGFR Epidermal growth factor receptor 8.01E-06 −1.5261
201285 MKRN1 Makorin ring finger protein 1 0.00033 −1.5139
225168 FRMD4A FERM domain containing 4A 0.00065 −1.5086
1565483 EGFR Epidermal growth factor receptor 4.11E-07 −1.5053
235993 PSMF1 Proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 0.00026 −1.505
Microarray differentially expressed genes between groups that passed FDR (5%).
TBI, traumatic brain injury; FDR, false discovery rate.
Additional larger studies are required to confirm our findings.
Additionally, our design did not allow for randomization. To
combat this limitation, we matched controls to blast-TBI partic-
ipants on diagnoses of sleep disturbance and symptom severity
of PTSD and depression. Although this allowed for isolation of
gene expression changes more related to blast-TBI, the hetero-
geneity of symptoms of PCD and times since the blast event
were issues that we were not able to address with the current
design. In addition, without a third comparison group with a TBI
not related to blast, we are unable to be certain that our find-
ings are related to blast-TBI. We were limited in not including
a clinician administered diagnostic tool to determine diagnoses
of PTSD and depression, which is an issue in this group of
patients who often present with complex symptoms that may be
psychosomatic in nature. We report high rates of comorbidity
in PCD, PTSD, and depression symptoms, as well as perceived
health declines (51), and greater psychosomatic illness severity
(52). Future larger studies that allow for comparison of differ-
ing symptom profiles of PCD and other comorbid symptoms will
provide insights into both the shared and unique gene-expression
pathways that underlie complex clinical presentations following
blast-TBI.
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Table 4 | Significantly up-regulated genes comparing blast-TBI+PCD (N =19) to control (N =17) groups.
Probe-set ID Gene symbol Gene title p-Value Fold-change
242539 DIS3L2 DIS3 mitotic control homolog (S. cerevisiae)-like 2 0.000341 1.7507
219787 ECT2 Epithelial cell transforming sequence 2 oncogene 0.000281 1.6386
218883 MLF1IP MLF1 interacting protein 8.53E-05 1.6065
1553696 ZNF569 Zinc finger protein 569 0.000737 1.5581
228859 C4orf21 Chromosome 4 open reading frame 21 0.000252 1.5335
231909 ODF2L Outer dense fiber of sperm tails 2-like 0.000284 1.5258
231899 ZC3H12C Zinc finger CCCH-type containing 12C 0.000174 1.5192
219174 IFT74 Intraflagellar transport 74 homolog (Chlamydomonas) 0.000763 1.5179
230165 SGOL2 Shugoshin-like 2 (S. pombe) 1.47E-05 1.5107
Microarray differentially expressed genes between groups that passed FDR (5%).
TBI, traumatic brain injury; FDR, false discovery rate.
FIGURE 1 | Generated molecular network based on differential
expression between traumatic brain injury (TBI) and control groups
using ingenuity knowledge database. Coloring is based on the
expression values of the genes (fold changes shown), down-regulation
in green and, up-regulation in red. Genes with no coloring are added
from ingenuity knowledge database. Direct and indirect relationships
are shown by solid and dashed lines, respectively. The arrow indicates
specific directionality of interactions. Genes with an asterisk indicate
that multiple identifiers (probe-sets) map to the gene in the molecular
network.
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Taken together, the identification of down-regulation in protein
ubiquitination and mediation of this pathway in gene expres-
sion, as well as down-regulation of EGFR and TNS1, suggest
involvement of these gene-expression pathways in chronic TBI
pathology. Both of these gene-pathways protect neurons from sec-
ondary injuries following TBI and are highly specific to neurons
(53, 54), and suggest that secondary injury or repair cascades can
be detected in a peripheral sample of blood from military person-
nel with blast-related injuries even when injuries are not acute.
Future studies are necessary to determine how variation in these
gene-expression pathways may contribute to the heterogeneity in
recovery from blast-TBI, as well as how manipulation of these
pathways through the administration of pharmacological agents
may promote recovery.
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